N/A
Completed N=27
Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain
Post-Operative Pain
Source: ClinicalTrials.gov NCT01861587 ↗
Enrolled (actual)
27
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcomePrimary: Patient Controlled Analgesia (PCA) Hydromorphone Usage — 12.6; 16.5 milligrams of hydromorphone
Summary
The purpose of this study is to determine whether a new medical technology can help reduce post-operative pain. The new technology is called Transcranial Direct Current Stimulation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Controlled Analgesia (PCA) Hydromorphone Usage |
12.6; 16.5 | — |
| PRIMARY Average Pain at Least |
4.5; 3.5; 3.2; 3.5 | — |
| PRIMARY Average Pain at Worst |
8.9; 8.0 | — |
| PRIMARY Average Pain |
7.0; 6.3 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years-75 years of age
- surgery at Medical University of South Carolina
- at least 2 days of post-operative stay
Exclusion Criteria
- history of seizures or epilepsy
- family history of seizures
- taking any medications shown to lower seizure threshold
- metal implants above the waist
- pregnant
- brain tumors or lesions
- pacemaker
Data sourced from ClinicalTrials.gov (NCT01861587). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.